Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of moderate rocuronium-induced neuromuscular blockade
PACTR201510001292136Not yet recruiting
- Sponsor
- shahira el metainy
- Start
- Oct 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Trial of Sugammadex, neostigmine and rocuronium in neuromuscular block (NMB), sponsored by shahira el metainy. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
Sugammadexneostigminerocuronium
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on PACTR201510001292136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201510001292136.